Nasdaq gnlx.

Genelux Corporation (NASDAQ:GNLX) rose 18.4% to $23.99. Shengfeng Development Limited (NASDAQ:SFWL) gained 17.2% to $6.09. Dunxin Financial Holdings Limited (NYSE:DXF) climbed 16.8% to $1.73.After-Hours Trades ... Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers ...GNLX Genelux Corporation Form 8-K - Current report. 0001231457 false 0001231457 2023-10-10 2023-10-10 iso4217:USD xbrli:shares ... Monitor; Level 2; Movers; Portfolio; Markets; Forums; Menu ...Price Target. $25.00. Profile Analyst Ratings Chart Competitors Earnings Financials Insider Trades Institutional Ownership Headlines SEC Filings Short Interest Social Media. Current. Insider Ownership. Percentage. 11.70%. Number Of.

Genelux ( NASDAQ: GNLX) said it has received fast-track status from the FDA for its Olvi-Vec program for the treatment of platinum resistant/refractory ovarian cancer. The company is currently ...What happenedShares of Genelux Corporation (NASDAQ: GNLX) were up by as much as 20.8% for the week on Thursday, according to data provided by S&P Global Market Intelligence. The healthcare company ...May 15, 2023 · WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 ...

WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 shares of the Company's common stock at a purchase price of $20.00 per share, for gross proceeds of approximately $18 million, …

WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the company as Chief Financial Officer, effective August 28, 2023. "I am excited to welcome Lourie to Genelux as our new Chief Financial Officer," said …WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second ...WebNov 1, 2023 · Fintel reports that on November 27, 2023, HC Wainwright & Co. initiated coverage of Genelux (NASDAQ:GNLX) with a Buy recommendation. As of November 1, 2023, the average one-year price target for ... Genelux Corporation (NASDAQ:GNLX) fell 8.7% to $10.83. Chegg, Inc. (NYSE:CHGG) shares declined 8.2% to $9.60. Morgan Stanley downgraded Chegg from Equal-Weight to Underweight and lowered the price ...

Find the latest Earnings Report Date for Genelux Corporation Common Stock (GNLX) at Nasdaq.com.

Genelux Corporation (NASDAQ:GNLX) fell 8.1% to $5.65. Genelux announced pricing of $15 million initial public offering of 2.5 million shares of common stock at a price of $6 per share.

May 25, 2023 · WESTLAKE VILLAGE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication of positive topline ... WESTLAKE VILLAGE, Calif. , Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023 , the Company’s Board of Directors (the “Board”) granted inducement awards consisting of non-qualified stock September 14, …WebGenelux Corporation (NASDAQ:GNLX) is a California based biotechnology firm that develops treatments for pancreatic, ovarian, and lung cancer. Its shares are rated Buy on average and analysts have ...Nov 24, 2023 · Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian ... GNLX stock had a volatile day of trading on September 19, 2023, with significant fluctuations in its price. The stock opened at $21.93 and ranged from $21.93 to $25.85 throughout the day. The trading volume for GNLX on September 19 was 14,269 shares, considerably lower than the average volume of 124,690 shares over the past …WESTLAKE VILLAGE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication of positive topline ...

Jan 21, 2023 · Companies that could price their IPOs and start trading include Genelux (NASDAQ:GNLX), Elate Group , MorningStar Partners , and Syla Technologies . Intel earnings ... Genelux Corporation Common Stock (GNLX) Real-Time Quotes | Nasdaq Real-Time: GNLX Edit my quotes Genelux Corporation Common Stock (GNLX) 0 Add to Portfolio GNLX GNLX REAL TIME GNLX...20. 11. 2023 ...Fintel. Fintel reports that on November 27, 2023, HC Wainwright & Co. initiated coverage of Genelux (NASDAQ:GNLX) with a Buy recommendation. Analyst Price Forecast Suggests 230.81% Upside As of ...Genelux Corporation (NASDAQ:GNLX) most popular amongst retail investors who own 57%, insiders hold 25%. Key Insights Significant control over Genelux by retail investors …WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as ...WebWESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the ...

GNLX U.S.: Nasdaq Genelux Corp. Watch list Set a price target alert After Hours Last Updated: Oct 10, 2023 6:54 p.m. EDT Delayed quote $ 23.00 0.97 4.40% After Hours Volume: 3.98K Advanced...Genelux Corporation is a late clinical-stage public company (Nasdaq: GNLX) developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the …

Shares of Genelux Corporation (NASDAQ:GNLX) got a boost, shooting 24% to $36.67. Sea Limited (NYSE:SE) shares were also up, gaining 16% to $76.09 after the company reported better-than-expected Q4 ...So far, 2023 has been a great year for Genelux Corporation (NASDAQ: GNLX), which has seen positive results from trials of its lead therapy Olvi-Vec (olvimulogene nanivacirepvec) that's primarily been active in studies pertaining to ovarian cancer. However, Genelux has also been forthcoming about its V2ACT Immunotherapy, which incorporates …Shares of Genelux ( GNLX 12.02%) were up 14.8% for the week, as of 9:30 a.m. ET Friday, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech company's stock ...WebWESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third ...WebView live Genelux Corporation chart to track its stock's price action. Find market predictions, GNLX financials and market news.Explore new charts. Discover historical prices for GNLX stock on Yahoo Finance. View daily, weekly or monthly format back to when Genelux Corporation stock was issued.American International Group Inc. bought a new position in Genelux Co. (NASDAQ:GNLX – Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,332 shares of the company’s stock, valued at approximately $44,000. A number of other institutional investors also recently modified their […]Genelux (NASDAQ:GNLX) PT Lowered to $30.00 americanbankingnews.com - November 25 at 3:58 AM: Genelux VP Sold $191K In Company Stock benzinga.com - November 23 at 12:58 PM: Genelux Corporation (NASDAQ:GNLX) most popular amongst retail investors who own 57%, insiders hold 25% finance.yahoo.com - November 17 at 8:49 AMGenelux Corporation (NASDAQ:GNLX) is a California based biotechnology firm that develops treatments for pancreatic, ovarian, and lung cancer. Its shares are rated Buy on average and analysts have ...Web

Genelux Co. (NASDAQ:GNLX – Free Report) – Brookline Capital Management reduced their FY2023 earnings per share (EPS) estimates for shares of Genelux in a research note issued on Tuesday, November 14th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings of ($1.03) per share for the year, down from their […]

WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the ...

Nasdaq provides company’s , which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all publicly ...Genelux (NASDAQ: GNLX) is owned by 15.88% institutional shareholders, 5.64% Genelux insiders, and 78.48% retail investors. Aladar Szalay is the largest individual Genelux shareholder, owning 555,000.00 shares representing 2.08% of the company. Aladar Szalay's Genelux shares are currently valued at $6.21M.Genelux (NASDAQ:GNLX) director Szalay Aladar continued to dispose of his stake in the biopharmaceutical company. Aladar sold 42,263 shares of indirect ownership, held by The Szalay 2010 Retained ...Nasdaq. 14,305.03 +78.81 (+0.55%) ... the Company’s shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “GNLX” on January 26, 2023 subject to final ...WebU.S. stocks traded higher, with the Nasdaq Composite gaining around 75 points on Tuesday. Here are some big stocks recording gains in today’s session. Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA ...Find the latest Earnings Report Date for Genelux Corporation Common Stock (GNLX) at Nasdaq.com. GNLX Genelux Corporation Form 4 - Statement of changes in beneficial ownership of securities. SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF ...Late clinical-stage immuno-oncology company, Genelux (NASDAQ:GNLX) announced a private placement of 1.67M shares at a price of $20 per share, for gross proceeds of approximately $33M.Proceeds from ...Nov 27, 2023 · Fintel. Fintel reports that on November 27, 2023, HC Wainwright & Co. initiated coverage of Genelux (NASDAQ:GNLX) with a Buy recommendation. Analyst Price Forecast Suggests 230.81% Upside As of ... Structure Therapeutics Inc. American Depositary Shares (GPCR) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.GNLX Genelux Corporation Form 4 - Statement of changes in beneficial ownership of securities. SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF ...WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation GNLX, a late clinical-stage immuno-oncology company, today announced that the United States Food and Drug ...

WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the ...WebCall and put options are quoted in a table called a chain sheet. The chain sheet shows the price, volume and open interest for each option strike price and expiration month. call and put options ...Mar 27, 2023 · Genelux ( NASDAQ: GNLX) is a recently IPO-ed phase 3 stage cancer therapeutics company. Its business is designing “oncolytic viral immunotherapies that are designed to generate a personalized ... So far, 2023 has been a great year for Genelux Corporation (NASDAQ: GNLX), which has seen positive results from trials of its lead therapy Olvi-Vec (olvimulogene nanivacirepvec) that's primarily ...Instagram:https://instagram. autazonewhat is a real estate investment firmupcoming shares splitdollar200 000 mortgage 30 years Oncolytic immunotherapy is an immunotherapy modality where viruses selectively replicate and kill tumor cells while leaving normal cells intact. Viral cell killing has the potential to expose all the tumor’s neoantigens to the immune system and to establish long-term antitumor immunity to improve outcomes for cancer patients. LEARN MORE.WESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted ... nasdaq cmrxfsd pharma Genelux Corp Follow Share $11.87 After Hours: $11.87 (0.00%) 0.00 Closed: Nov 17, 4:02:25 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare to SHENGFENG DEVELOPMENT Ltd $11.23 SFWL1.91%...Genelux Corporation Common Stock (GNLX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. ticker uvxy Follow. WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of ...WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second ...